ArticleJournal of pain research2026
Liposomal Bupivacaine for Serratus Anterior Plane Block in Modified Radical Mastectomy: Protocol for a Randomized, Double-Blind Trial Evaluating Pain-Related and Early Recovery Outcomes.
Article in Journal of pain research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Modified radical mastectomy is commonly associated with substantial postoperative pain, opioid use and impaired early recovery. Serratus anterior plane block (SAPB) is increasingly used as part of multimodal analgesia for breast surgery. Although SAPB and quality of recovery outcomes have both been studied in breast surgery, published evidence regarding the use of liposomal bupivacaine in SAPB for modified radical mastectomy remains limited. This trial was designed to address whether adding liposomal bupivacaine to bupivacaine hydrochloride (bupivacaine HCl) for SAPB improves pain-related and early recovery outcomes after surgery. Patients and Methods: This is a prospective, randomized, double-blind, controlled trial. Seventy-six patients undergoing elective modified radical mastectomy for breast cancer are being randomly assigned in a 1:1 ratio to receive unilateral ultrasound-guided SAPB after induction of general anesthesia and before skin incision with either liposomal bupivacaine plus bupivacaine HCl (Group L) or bupivacaine HCl alone (Group B). The primary endpoint is the Quality of Recovery-15 (QoR-15) score at 24 h postoperatively. Secondary outcomes include postoperative pain intensity up to 72 h, opioid-related outcomes expressed as morphine milligram equivalents (MME), QoR-15 scores at 48 and 72 h, time to first demand of patient-controlled analgesia (PCA), Overall Benefit of Analgesia Score (OBAS), postoperative nausea and vomiting, sleep quality, perioperative complications and patient-reported neuropathic pain symptoms at 3 months assessed using the Douleur Neuropathique 4 interview (DN4i). The primary analysis will follow the intention-to-treat (ITT) principle. Prespecified sensitivity analyses will include a modified ITT (mITT) set excluding participants who did not receive the allocated SAPB injection and an exploratory per-protocol (PP) set excluding major protocol deviations. Conclusion: This trial will evaluate whether adding liposomal bupivacaine to bupivacaine HCl for SAPB provides additional benefit for pain-related and early recovery outcomes after modified radical mastectomy compared with SAPB using bupivacaine HCl alone. Trial Registration: Chinese Clinical Trial Registry, Registration No. ChiCTR2500111732. Registered on 5 November 2025.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.